Targeted Bio-Orthogonal Prodrug Activation

The invention relates to an improved method for targeted activation of prodrugs using bio-orthogonal chemical reactions, enhancing specificity, safety, and efficacy.

The original patent disclosed bio-orthogonal drug activation methods, but limitations included lack of targeting specificity, potential off-target effects, and inefficient activation. The new inventive concept addresses these limitations by introducing targeted delivery and activation mechanisms.

The new concept comprises a trans-cyclooctene derivative and a compatible diene, wherein the diene is conjugated to a targeting moiety or encapsulated in a nanoparticle, ensuring specific site activation. The bio-orthogonal chemical reaction is triggered by enzymatic activity or targeted delivery, enhancing efficiency and reducing off-target effects.

The new claims introduce the concept of targeted delivery and activation of prodrugs using bio-orthogonal chemical reactions, which is not obvious from the original patent. The use of trans-cyclooctene derivatives, compatible dienes, and targeting moieties or nanoparticles provides a novel and non-obvious solution to the limitations of the original patent.

Alternative embodiments include using different targeting moieties or nanoparticles, varying the structure of the trans-cyclooctene derivative and compatible diene, and exploring different enzymatic triggers for the bio-orthogonal reaction.

The targeted bio-orthogonal prodrug activation concept has potential applications in cancer therapy, autoimmune disease treatment, and other areas where targeted drug delivery is crucial. The market for targeted therapies is growing, and this invention offers a competitive advantage in terms of specificity, safety, and efficacy.